CTNM

Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company located in San Diego, California, focused on developing innovative oral small molecule therapies to address significant unmet medical needs in neuroscience, inflammation, and immunology. The company boasts a robust pipeline driven by advanced research capabilities and a commitment to scientific excellence, positioning itself to deliver effective treatments that enhance patient outcomes. With a strategic focus on addressing critical healthcare challenges, Contineum is poised for substantial growth within the biopharmaceutical industry, making it an attractive prospect for institutional investors.